血清IL-10水平判断卡介苗膀胱灌注治疗T<sub>1</sub>非肌层浸润性膀胱癌预后的价值

Abstract
Figure/Table
References
Related Citation (7)

Download: PDF (1346 KB) HTML (0 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To investigate the value of serum IL-10 level in evaluating the prognosis of bacillus calmette-guerin (BCG) bladder perfusion therapy in the treatment of T1 non-muscular invasive bladder cancer (NMIBC). Methods A retrospective cohort study was conducted on 149 patients with high-risk T1 NMIBC who received BCG bladder perfusion therapy and transurethral electrotomy for bladder tumor (TURBT) from January 2017 to December 2021. General data of patients were collected and blood routine results of patients with TURBT 1 week before surgery were recorded. The results of cystoscopy were recorded and analyzed 3 months after operation. Serum samples were collected before and during BCG induction therapy, and serum IL-10 levels were detected by human IL-10 enzyme-linked immunosorbent assay kit, and comparative analysis was performed. Results Among 149 cases, 45 cases recurred within 6 months after induction therapy and were considered as non-responders to BCG, and the other 104 patients were considered responders. Serum IL-10 levels in non-responders were significantly higher than those in non-responders before BCG infusion into the bladder (baseline), in the early and middle stages of induction therapy and after treatment (P＜0.05). When baseline serum IL-10≥242.55 pg/ml, the area under the receiver operating characteristic curve (AUC) for predicting BCG treatment response was 0.729, the sensitivity was 66.70%, and the specificity was 74.0%. Changes in serum IL-10 levels from baseline to the last time point also distinguished well between BCG responders and non-responders (AUC=0.676). During a median follow-up of 42 months, 69 cases of tumor recurrence occurred. Patients were divided into high-risk group and low-risk group with median GSIL-10 value. The high risk group had a shorter recurrence-free survival (RFS) (P＜0.001) and a lower RFS rate (P=0.011) than the low risk group. COX proportional hazard regression analysis confirmed that high serum IL-10 level at baseline (HR=2.042, P=0.007) was an important variable for tumor recurrence in patients treated with BCG bladder perfusion. Conclusions Serum IL-10 may be a reliable marker for predicting the response and prognosis of NMIBC to BCG.

Key words： bacillus calmette-guerin bladder perfusion therapy interleukin Il-10 non-muscular invasive bladder cancer recurrence-free survival treatment response

Received: 17 May 2024

ZTFLH:

R737.14

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	WANG Kaijian
	HUANG Wei
	LI Wei
	SHEN Hongfeng

Cite this article:

WANG Kaijian,HUANG Wei,LI Wei等. Value of serum IL-10 level in evaluating the prognosis of bacillus calmette-guerin bladder perfusion therapy in the treatment of T1 non-muscular invasive bladder cancer[J]. Med. J. Chin. Peop. Armed Poli. Forc., 2024, 35(10): 860-866.

URL:

https://journal08.magtechjournal.com/Jwk_wjyx/EN/ OR https://journal08.magtechjournal.com/Jwk_wjyx/EN/Y2024/V35/I10/860

[1]	陈如串, 刘伟, 周冰妮, 等. VI-RADS联合肿瘤基底接触长度检测肌层浸润性膀胱癌的价值研究[J]. 中国癌症杂志, 2023, 33(3): 260-266.
[2]	Bhindi B, Kool R, Kulkarni GS, et al. Canadian Urological Association guideline on the management of non muscle invasive bladder cancer Full text[J]. Can Urol Assoc J, 2021, 15(8): E424-E460.
[3]	Babjuk M, Burger M, Compérat E M, et al. European association of urology guidelines on non-muscle-invasive bladder cancer (tat1 and carcinoma in situ) - 2019 update[J]. Eur Urol, 2019 , 76(5): 639-657.
[4]	Wang Z, So W Z, Loh K Y, et al. Predictive biomarkers of response to bacillus Calmette-Guérin immunotherapy and bacillus Calmette-Guérin failure for non-muscle invasive bladder cancer[J]. Int J Urol, 2022, 29(8): 807-815.
[5]	Queiroz N M, Marinho F V, Araujo A C, et al. MyD88-dependent BCG immunotherapy reduces tumor and regulates tumor microenvironment in bladder cancer murine model[J]. Sci Rep, 2021, 11(1): 15648.
[6]	孙卫兵, 刘志宇, 李泉林, 等. 卡介苗膀胱灌注预防中、高危非肌层浸润性膀胱癌复发的疗效及并发症分析[J]. 中华泌尿外科杂志, 2019, 40(1): 14-19.
[7]	辛士永, 李亮亮, 吴硕, 等. 吉西他滨联合卡介苗膀胱灌注预防高危非肌层浸润性膀胱癌术后复发的效果[J]. 中国老年学杂志, 2019, 39(5): 1064-1068.
[8]	Song D, Powles T, Shi L, et al. Bladder cancer, a unique model to understand cancer immunity and develop immunotherapy approaches[J]. J Pathol, 2019, 249(2): 151-165.
[9]	Mukherjee N, Julián E, Torrelles J B, et al. Effects of Mycobacterium bovis Calmette et Guérin (BCG) in oncotherapy: Bladder cancer and beyond[J]. Vaccine, 2021, 39(50): 7332-7340.
[10]	彭娇, 何卫阳. 肿瘤相关巨噬细胞在膀胱癌免疫治疗中的研究进展[J]. 癌症进展, 2022, 20(3): 234-237.
[11]	Wigner P, Grębowski R, Bijak M, et al. The interplay between oxidative stress, inflammation and angiogenesis in bladder cancer development[J]. Int J Mol Sci, 2021, 22(9): 4483.
[12]	Jang D, Lee A H, Shin H Y, et al. The role of tumor necrosis factor alpha (TNF-α) in autoimmune disease and current TNF-α inhibitors in therapeutics[J]. Int J Mol Sci, 2021, 22(5): 2719-2733.
[13]	王金泗, 张辉, 林彩玲, 等. M2巨噬细胞分泌的IL-10通过JAK2/STAT3信号通路调节乳腺癌细胞的增殖、侵袭与凋亡[J]. 免疫学杂志, 2020, 36(10): 838-845.
[14]	王彩红, 高春, 于晓辉, 等.靶向TIGIT肿瘤免疫治疗的研究进展[J]. 武警医学, 2023, 34(5):438-442.
[15]	Saraiva M, Vieira P, O'Garra A. Biology and therapeutic potential of interleukin-10[J]. J Exp Med, 2020, 217(1): e20190418.
[16]	彭丽娜, 武川军, 冯志星, 等. IDO1和IL-10在喉鳞状细胞癌组织中的表达及其与临床病理特征和预后的关系研究[J]. 中国现代医学杂志, 2022, 32(1): 69-74.
[17]	Widodo S S, Dinevska M, Furst L M, et al. IL-10 in glioma[J]. Br J Cancer, 2021, 125(11): 1466-1476.
[18]	Cai T, Nesi G, Mazzoli S, et al. Prediction of response to bacillus Calmette-Guérin treatment in non-muscle invasive bladder cancer patients through interleukin-6 and interleukin-10 ratio[J]. Exp Ther Med, 2012, 4(3): 459-464.